Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool December 26, 2006 Brian Lawler	InterMune's Secret Drug Surprise Shares of InterMune have risen after positive trial results for one of its top drug candidates. Investors, take note.
The Motley Fool December 17, 2010 Brian Orelli	An Overnight Double: Santa Visits InterMune in Europe The Committee for Medicinal Products for Human Use issued a positive recommendation for the approval of InterMune's idiopathic pulmonary fibrosis treatment, Esbriet, sending shares up 140%.
The Motley Fool February 3, 2009 Brian Orelli	InterMune Batting .500 The results weren't exactly what Rule Breakers pick InterMune was looking for, but things could have been worse -- and the stock is up 38% today on the news.
The Motley Fool March 10, 2010 Brian Orelli	Up 160% With Room to Run You've got to love biotech and InterMune.
The Motley Fool March 6, 2007 Brian Lawler	InterMune Swoons Shares of InterMune fall after it announces negative clinical trial results for one of its drugs.
The Motley Fool March 21, 2007 Brian Lawler	InterMune Slims Down InterMune announces changes after its lead compound fails in a study. Investors, take note.
The Motley Fool March 8, 2010 Brian Orelli	Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting.
The Motley Fool October 7, 2010 Brian Orelli	Asset Sold, Questions Begin Why did InterMune sells its stake in danoprevir?
The Motley Fool September 24, 2007 Brian Lawler	Encysive Hears the Voice of Reason To please the FDA, Encysive Pharmaceuticals announces it is planning an additional phase 3 trial to try and bring its lead drug, Thelin, to market in the United States.
The Motley Fool April 30, 2004 Charly Travers	Sales Weakness From InterMune Biotechnology company InterMune would seem to be in good shape with a drug, Actimmune (which helps boost the immune system of cancer patients and others). The drug, however, has been showing quarterly sales weakness since early 2003, a trend that now seems like it may continue into the future.
The Motley Fool January 3, 2011 Brian Orelli	Clinical Trial Results Fail to Inspire Inspire Pharma gets cut in half after a cystic fibrosis trial failure.
The Motley Fool December 31, 2010 Brian Orelli	2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions.
The Motley Fool August 4, 2005 Charly Travers	This One's a Winner Encysive awaits FDA approval, and all signs are positive. Biotech investors, take note.
The Motley Fool May 3, 2010 Brian Orelli	While You Were Reveling in Dendreon's Win The FDA has approved Vimovo, an arthritis drug from Pozen and AstraZeneca, and Bristol-Myers Squibb also got a decision from the FDA, but it wasn't the positive kind.
The Motley Fool January 31, 2011 Brian Orelli	5 Drugmakers Headed Back to the Drawing Board Sometimes an FDA rejection is more of a to-do list.
The Motley Fool June 29, 2009 Brian Orelli	Gilead Says "Pleeeease." EU Says "Well, OK." This appeal actually resulted in an approved drug.
The Motley Fool December 7, 2006 Brian Lawler	The Best Small Cap for 2007: Encysive Pharmaceuticals This little drug maker has the potential for big profit, in both the U.S. and Europe. Investors, take note.
The Motley Fool June 18, 2007 Brian Lawler	The Third Time Isn't the Charm for Encysive The approvable letter for the pulmonary arterial hypertension treatment marks the third time Thelin has failed to get full approval from the FDA. Investors, take note.
The Motley Fool September 6, 2007 Brian Lawler	Encysive, Please Stop Its failure to acquiesce to the FDA's request means the competition is going forward as this drugmaker's product stays stagnant. Investors, take note.
The Motley Fool February 22, 2008 Brian Lawler	The Hypertension Fight Expands News from the pharmaceutical industry regarding hypertension medications: Gilead and Glaxo win E.U. approval for a drug, and Encysive's sellout came just in time.
The Motley Fool April 3, 2008 Brian Lawler	Will InterMune's Hepatitis C Drug Compete? InterMune announces positive data for its hepatitis C treatment drug.
The Motley Fool September 6, 2007 Brian Lawler	Foolish Fantasy Football: InterMune on Special Teams This stock analyst chooses developmental stage drugmaker InterMune as his speculative bet.
The Motley Fool December 20, 2010 Brian Orelli	A Good Fit. On the Surface. Digging a little deeper into Gilead's acquisition of Arresto.
Chemistry World August 29, 2014 Sarah Houlton	Roche to buy InterMune for respiratory boost Roche is to acquire InterMune in a deal worth $8.3 billion.
The Motley Fool November 5, 2007 Brian Lawler	Encysive in a No-Win Situation Encysive Pharmaceuticals needs help to get its lead drug onto the U.S. market in time to turn its financials around. Investors, take note.
The Motley Fool January 8, 2008 Brian Lawler	InterMune Goes Step by Step The company updates investors on the progress of its lead drug for hepatitis C.
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
The Motley Fool November 17, 2010 Brian Orelli	52 Years Down, 1 Month to Go Lupus treatment Benlysta moves closer to approval.
The Motley Fool March 11, 2010 Jim Mueller	Is Medivation a Buy? What is the thinking with regards to Medivation today? It already got a big haircut last week. Is it worth investing in at these lower prices?
The Motley Fool March 7, 2007 Brian Lawler	Encysive's Outback Adventures The pharmaceutical gains marketing approval for its lead compound in Australia. Investors, take note.
The Motley Fool January 28, 2008 Brian Lawler	Can Encysive Catch the Competition? After two years of spectacular mismanagement, will 2008 be the year that Encysive Pharmaceuticals is finally able to capitalize on its very marketable lead drug, Thelin?
The Motley Fool September 13, 2007 Brian Orelli	Alfacell's Awkward Wait Waiting for subjects to die is a somber part of the oncology clinical trial process. Alfacell is doing just that in its final phase three trial with its lead cancer drug candidate. Investors take note.
The Motley Fool August 9, 2010 Jim Mueller	3 Stocks to Play Biotech Three promising ideas for investing in this exciting area.
The Motley Fool May 18, 2009 Brian Orelli	Is There Life After 600% Returns? Just because a drug company gets a massive increase in the stock price after a positive clinical trial or an FDA approval, that doesn't mean all the growth is completely factored into the stock price.
The Motley Fool April 3, 2009 Brian Orelli	Gilead: Helping Investors Cope With the Market Diversifying seems to be paying off for the drugmaker.
The Motley Fool June 15, 2007 Brian Lawler	Encysive's Date With Destiny Approaches A decision on the specialty drugmaker's lead drug is imminent. Betting against the FDA is generally not a good idea for investors. Here are statements from Encysive's past press releases about Thelin
The Motley Fool February 21, 2007 Brian Lawler	Gilead Closes the Gap The FDA trims Gilead's review period for a top developmental compound. Investors, take note.
The Motley Fool August 7, 2007 Brian Lawler	Encysive's Congested Sales Failure Encysive Pharmaceuticals releases quarterly results that reveal a company with problems. Its cost structure is way out of line for a drugmaker of its size and potential.
The Motley Fool December 16, 2009 Brian Orelli	Gilead's Phase 3 Train Wreck Gilead Sciences' darusentan looked so promising.
The Motley Fool December 31, 2011 Brian Orelli	3 Stock-Moving Binary Events to Watch in 2012 Binary events, FDA decisions, and clinical trial results, are the lifeblood -- and death wish -- of the biotech industry. Here are three to watch in 2012.
The Motley Fool July 19, 2007 Brian Lawler	Will Encysive's FDA Challenge Fail? The pharmaceutical gets set for a showdown with the FDA. Investors should think long and hard about whether shares of Encysive are worth holding, considering that the likely result of this dispute resolution process won't be positive.
The Motley Fool December 11, 2006 Brian Lawler	Another Go for Encysive Drug Trials Sometimes shares of small specialty-pharma stocks rise and fall much more than warranted on every piece of news, and this appears to have happened to Encysive Pharmaceuticals.
The Motley Fool August 17, 2007 Brian Orelli	Fewer Drug Approvals? Buy! Stricter standards at the FDA could create a buying opportunity. Drug approvals are down one third this year, creating a lot of value in pharmaceutical and biotech companies. Just choose your medicines carefully.
The Motley Fool March 1, 2007 Brian Lawler	Know Your Drug Stock ABCs: Part 2 Investing in the pharmaceutical and biotechnology industries can be difficult. Here are terms investors should know to better understand how the clinical trial process involved with bringing a drug to market works.
The Motley Fool October 30, 2009 Brian Orelli	Earnings? Yawn. Trial Data? Moving! For Human Genome Sciences investors, the anticipation is frightening.
The Motley Fool August 18, 2011 Brian Orelli	Running the Correct Trial Isn't Enough MELA Sciences' stock is up on claim that their trial meets FDA guidance, but they still need to prove that the device actually works.
The Motley Fool February 21, 2008 Brian Lawler	Learn From the Decisive Encysive Deal Encysive finally finds a buyer; Pfizer announces it will acquire the drugmaker for $195 million in cash.
The Motley Fool December 15, 2011 David Williamson	1 Massive Biotech Bloodbath Trial results and FDA panels ruled the health-care sector today.
The Motley Fool July 24, 2007 Brian Lawler	Discounting InterMune Shares of InterMune fall after analyst worries about one of its drugs. Investors looking to buy into the next blockbuster class of hepatitis C treatments on the cheap just got their chance.
The Motley Fool April 15, 2011 Brian Orelli	Fewer Needle Pricks for the Europeans Amylin's once-weekly diabetes drug Bydureon gets a positive recommendation in Europe.